48-week follow-up of a RCT | Pegcetacoplan vs. Eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
8 Sep, 2022 | 14:29h | UTCPegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)
Original Study: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine
Commentary on Twitter (thread – click for more)
NEW research—Duration of improved haem outcomes and favourable safety over 48 weeks suggests that pegcetacoplan has the potential to alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria: long-term results of PEGASUS #PNH https://t.co/dpT5cDih8X
— The Lancet Haematology (@TheLancetHaem) September 1, 2022